Evidence map›Paper›PMID 41266757›Full record

ArticleScientific reports2025

Formulation and evaluation of taste-masked curcumin nanoparticles for improved antioxidant and anticancer efficacy.

Mulham Alfatama, Zalilawati Mat Rashid, Omar A Harasstani, Hamzeh Alkhatib, Asif Nawaz, Hazem Choukaife

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mulham AlfatamaFaculty of Pharmacy, Universiti Sultan Zainal Abidin, Besut Campus, 22200, Terengganu, Malaysia. mulham4122@yahoo.com.
Zalilawati Mat RashidSchool of Food Industry, Faculty of Bioresources and Food Industry, Universiti Sultan Zainal Abidin, Besut Campus, 22200, Besut, Terengganu, Malaysia.
Omar A HarasstaniFaculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur (RCMP UniKL), 30450, Ipoh, Perak, Malaysia.
Hamzeh AlkhatibFaculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur (RCMP UniKL), 30450, Ipoh, Perak, Malaysia.
Asif NawazDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia.
Hazem ChoukaifeFaculty of Pharmacy, Universiti Sultan Zainal Abidin, Besut Campus, 22200, Terengganu, Malaysia. hazemchoukaife@gmail.com.

Funding

Malaysian Ministry of Higher Education (MOHE) Fundamental Research Grant Scheme (FRGS) FRGS/1/2022/SKK16/UNISZA/03/2, project code RR451.
6 · The paper itself

Abstract

Curcumin, a natural polyphenolic compound derived from turmeric, is well-documented for its therapeutic properties, including anti-inflammatory, antioxidant, antimicrobial, and anticancer activities. However, its clinical and nutraceutical applications are limited by its poor aqueous solubility, low oral bioavailability, and unpleasant taste. This study aimed to encapsulate curcumin in alginate-based nanoparticles, with and without chitosan coating, to improve its palatability while preserving its therapeutic efficacy. Two optimized formulations uncoated curcumin-loaded alginate nanoparticles (CANPs) and chitosan-coated nanoparticles (CANPs-Cs) were developed, exhibiting average particle sizes of 199.51 ± 9.40 nm and 312.90 ± 10.30 nm, polydispersity indices of 0.26 ± 0.090 and 0.27 ± 0.09, zeta potentials of - 23.10 ± 1.10 mV and + 28.50 ± 1.00 mV, encapsulation efficiencies of 93.6 ± 3.5% and 90.8 ± 0.1%, and drug loading of 1.32 ± 0.15% and 1.25 ± 0.19%, respectively. FTIR analysis confirmed the compatibility and successful encapsulation of curcumin within the nanoparticle matrix. The chitosan-coated formulation (CANPs-Cs) exhibited enhanced antioxidant activity and superior taste-masking ability, as evidenced by a significant reduction (~ 50%) in curcumin release within artificial saliva compared to CANPs. Additionally, both formulations demonstrated potent cytotoxic effects against the CT26 colon cancer cell line, with CANPs-Cs maintaining therapeutic efficacy while offering improved sensory attributes. These findings suggest that CANPs-Cs is a promising delivery system for curcumin, offering enhanced bioactivity and palatability suitable for food and pharmaceutical applications.

Indexed as

Antineoplastic AgentsAntioxidantsCurcuminNanoparticlesTasteAlginatesCell Line, TumorChitosanDrug CompoundingHumansParticle SizeAlginatesAntineoplastic AgentsAntioxidantsChitosanCurcuminAnticancerCurcuminNanoparticlesPalatabilityTaste masking

Identifiers

PMID41266757
PMCPMC12635348

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.